KOSDAQBiotech & Pharma053950

Kyung Nam Pharm

₩1,426▲ 0.14%2026-11-18 close
Market Cap
₩28B
Turnover
₩22,840,745
Volume
20K
Shares out.
19.6M
PER
—
PBR
0.2×
EPS
-₩583
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Sales Rising, Losses Persist at Lemona-Centered Kyung NAM Pharm

Kyung NAM Pharm's Q3 2026 revenue rose 46.2% year on year to KRW 20.7 billion, but the operating loss widened to KRW 1.31 billion, so top-line growth has not yet reached profitability.

  1. 1

    Top line: sales peaked at KRW 68.4 billion in 2023 and fell to KRW 55.9 billion in 2025, but have increased for four consecutive quarters from Q4 2025 through Q3 2026.

  2. 2

    Profitability: the company recorded operating losses in each year from 2022 to 2025, with a KRW 1.73 billion loss and a -3.1% operating margin in 2025, and operating losses have continued through Q2 and Q3 2026.

  3. 3

    Balance sheet and cash: the debt ratio fell from 85.5% in 2023 to 43.7% at end-2025, while operating cash flow turned negative at -KRW 1.68 billion in 2025.

  4. 4

    Business: OTC drugs, general foods and health functional foods account for most sales, and the company is widening distribution through pharmacies, convenience stores and Olive Young.

  5. 5

    Capital: a 5-to-1 reverse stock split took effect in April 2026, and reports in October 2026 said the KRW 19.085 billion rights offering was withdrawn, changing the funding plan.

02

Business structure

Kyung NAM Pharm is a consumer-oriented company built around the vitamin brand Lemona, combining pharmaceutical manufacturing with direct sales.

According to a Newsdaily report on 2025 results, sales were split into OTC drugs at 41.8%, general foods at 26.2%, health functional foods at 18.6% and quasi-drugs at 11.5%, while ethical drugs (1.83%) and active pharmaceutical ingredients (1.88%) each remained below 2%.

In the first half of 2026, per the semi-annual report, Lemona Acid generated KRW 8.376 billion, or 24.7% of major product sales, followed by Jahasaengryeok at KRW 3.177 billion, Kalo at KRW 1.784 billion, Gyeol Collagen at KRW 1.597 billion, PM at KRW 1.288 billion and Minol at KRW 758 million.

Products reach roughly 24,000 outlets including pharmacies, convenience stores and large marts, and a sales organization of 11 regional branches covers the pharmacy channel.

In February 2026 the company signed a co-marketing deal with SK Chemicals for the allergic rhinitis drug Nozal soft capsules, adding third-party products to its pharmacy sales network.

In 2026 it launched seven new products, including Lemona Drink Zero and Lemona Welemon in April and Lemona Daily Vitamin C 3000, Kalo-Cut&Reset, Naikan tablets and Garenkul capsules between July and September.

Welemon was first sold at the convenience chain CU, and Kalo entered Olive Young through a Sanrio Characters bundle. Production is centered on the Asan plant in Chungcheong, which has powder, tablet and capsule lines.

Past industry coverage described the vitamin market as crowded with many pharmaceutical companies, so brand strength and distribution reach remain the key competitive variables.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩14.2B-₩1.1B−7.5%
2025Q4₩14.7B₩66,261,7030.5%
2026Q1₩16.1B₩400M2.3%
2026Q2₩17.8B-₩200M−1.2%
2026Q3₩20.7B-₩1.3B−6.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩59B-₩3.4B-₩6.8B−5.7%−6.8%44.7%
2023₩68.4B-₩6.7B-₩21B−9.9%−26.5%85.5%
2024₩60.8B-₩900M₩10.1B−1.6%8.7%44.6%
2025₩55.9B-₩1.7B-₩9B−3.1%−8.3%43.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual results show diverging sales and profitability. Revenue rose from KRW 59 billion in 2022 to KRW 68.4 billion in 2023, a 16.0% increase, and then declined 11.2% to KRW 60.8 billion in 2024 and 8.0% to KRW 55.9 billion in 2025, a two-year decline.

Operating losses were KRW 3.39 billion in 2022, KRW 6.74 billion in 2023, KRW 943 million in 2024 and KRW 1.73 billion in 2025, a run of four consecutive loss-making years, with the operating margin at its lowest in 2023 at -9.9%.

Attributable net income turned positive at KRW 10.1 billion in 2024, but consolidated net income of KRW 8.64 billion that year was driven largely by a one-off gain from discontinued-operations disposal, according to a Newsdaily analysis.

In 2025 attributable net loss widened to KRW 9.01 billion, which the company attributed to a larger operating loss, lower financial income and an impairment loss on investment property. This recurring dependence on non-operating items is a defining feature of the earnings record.

The same report noted that the cost ratio rose for a second year to 72.9% in 2025, and that lower selling and administrative expenses did not offset the widening operating loss.

Quarterly figures show Q4 2025 revenue of KRW 14.7 billion, up 3.4% from the prior quarter, with an operating profit of KRW 66.26 million, a swing to profit. Q1 2026 revenue reached KRW 16.1 billion with an operating profit of KRW 377 million, up 469.4% from the prior quarter.

Q2 2026 returned to an operating loss of KRW 212 million, and Q3 2026 revenue of KRW 20.7 billion, up 46.2% year on year, came with a widened operating loss of KRW 1.31 billion.

Attributable net losses were KRW 705 million in Q1 2026, KRW 3.12 billion in Q2 and KRW 2.32 billion in Q3, and the attributable net loss for the last four quarters totals KRW 11.4 billion.

A report based on the quarterly filing put January to September 2026 revenue at KRW 54.6 billion with an operating loss of KRW 1.1 billion.

05

Industry analysis

Consumer health markets in Korea, covering OTC vitamins, collagen products and health functional foods, are intensely competitive in distribution.

Kyung NAM Pharm has long brand recognition in vitamin C products, yet past industry coverage described the vitamin market as saturated, with many pharmaceutical companies entering. Expanding into non-pharmacy channels such as Olive Young and the CU convenience chain in 2026 reads as a response to that saturation.

On production, the Asan plant had an annual capacity of KRW 41.05 billion according to the 2025 annual report, with average utilization of 49.73% for powders, 68.58% for tablets and 27.11% for capsules.

Utilization below 50% for powders and capsules suggests that raising the output of existing lines is a more immediate task than new capacity. Media reported government pressure on pharmaceutical companies to restructure, and Maeil Business reported that the company planned to invest KRW 12 billion in marketing.

Compared with ethical-drug-focused listed peers, the sales mix leans toward OTC drugs and foods, so direct exposure to drug price regulation is comparatively limited.

Consumer-type products, however, move quickly with advertising efficiency and shelf-entry terms, which makes marketing spending the central swing factor for profitability. The Q3 2026 operating loss widening despite higher sales shows that this lever has not yet translated into earnings.

06

Outlook

Three lines of business plans have been disclosed. The first is manufacturing capacity.

In November 2025 the company disclosed plans to expand manufacturing facilities at the Asan plant and install new equipment, including extraction equipment for placenta-based ingredients and expanded external liquid manufacturing lines. The second is products and channels.

The company launched seven new products in 2026 and said Welemon would add sales points beyond CU, with plans to widen the Lemona and Kalo lines on Olive Young and similar channels. The third is new business.

A shareholder meeting agenda in May 2026 proposed adding liquor import-export and liquor distribution and sales to the articles of incorporation, and pet supply businesses were also part of the plan. A company official said the type of liquor and target overseas markets have not been decided.

On funding, a KRW 19.085 billion rights offering disclosed in May 2026 was reported in October 2026 as withdrawn, which changes how operating funds will be raised. The company had earlier said the proceeds would go to product marketing and raw material costs.

In the first half of 2026, quarterly operating results moved from a Q1 profit to a Q2 loss, so the trajectory of later quarters is the main test of whether the product and channel expansion is working.

The 2026 annual report, the next periodic filing, will provide the most direct readings of the operating margin and operating cash flow.

07

Valuation

PER
—
PBR
0.2×
ROE
-10.4%
EPS
-₩583
BPS
₩6,360
Dividend per share
₩0

Earnings-based valuation metrics are hard to read at this stage. Because the last four quarters show net losses, the price-to-earnings ratio cannot be calculated, and until profit returns there is little basis for comparing earnings multiples with a past trading band.

By contrast, the price-to-book ratio sits well below 1x, meaning the market values the company at a steep discount to its book equity.

Total equity was KRW 108.3 billion at end-2025 against liabilities of KRW 47.3 billion, and the debt ratio fell from 85.5% in 2023 to 43.7% in 2025, so the balance sheet has strengthened.

Market capitalization is below total equity, which makes the market's willingness to credit the company's net assets the starting point for interpreting the share price. Dividend payouts are close to nil, so shareholder returns measured by dividend yield are low.

The company posted a one-off profit in 2024 from a discontinued-operations gain and returned to losses in 2025, so any comparison against net assets is also shaped by one-off items.

Impairment on investment property and fair-value losses on financial assets have moved reported results, making the carrying value of those assets a further variable.

For valuation, the more useful markers are whether operating profit turns positive and how the capital structure changes, rather than the share price level itself.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Sales growth has persisted

Q3 2026 revenue reached KRW 20.7 billion, up 46.2% year on year, and sales have risen for four consecutive quarters from Q4 2025 through Q3 2026.

In the first half of 2026, Lemona Acid accounted for 24.7% of major product sales, with the remaining product lines making up about 75%, so reliance on a single product is spread across the portfolio.

Distribution diversification has started

Seven new products launched in 2026, Olive Young listings began, Welemon entered CU, and a co-marketing deal with SK Chemicals opened the pharmacy sales network to third-party products. Selling outside products can raise utilization of the existing sales organization and add revenue. Reducing dependence on the pharmacy channel is a strength in this setup.

Balance sheet and quarterly loss narrowing

The debt ratio fell from 85.5% in 2023 to 43.7% in 2025, and total equity stood at KRW 108.3 billion at end-2025. Attributable net loss narrowed from KRW 3.12 billion in Q2 2026 to KRW 2.32 billion in Q3, and Q1 2026 posted an operating profit of KRW 377 million.

09

Bear factors

Operating losses continue

Annual operating losses ran from 2022 through 2025, and operating losses continued in Q2 and Q3 2026. The Q3 2026 operating loss of KRW 1.31 billion was wider than a year earlier. The fact that higher sales have not converted into profit is the most significant weakness.

Cost pressure and weaker cash flow

According to a Newsdaily report, the cost ratio rose for a second straight year to 72.9% in 2025. Operating cash flow turned negative at -KRW 1.68 billion in 2025. The Q1 2026 profit shows how volatile quarterly results have been.

Funding and management stability concerns

Media reports describe repeated reverse splits, capital reductions and rights offerings, along with frequent changes of chief executive. Reports of a withdrawn 2026 rights offering have made the funding route for operations less certain. Some industry observers also say the company's Lemona-centered model is weakening brand competitiveness.

10

Risk factors

Funding and financial risk

Reports of a withdrawn 2026 rights offering mean the planned funding has not proceeded as intended. A Newsdaily analyst said continued operating losses and cash flow pressure could lead to additional risks such as designation as a managed stock.

Cash and cash equivalents were reported to have fallen from KRW 50.8 billion at end-2024 to KRW 6.2 billion at end-2025.

Business concentration risk

Sales are concentrated in OTC drugs, general foods and health functional foods, while ethical drugs and active pharmaceutical ingredients each account for less than 2%. Results are sensitive to a small number of products such as Lemona Acid and to consumer trends. If marketing spending does not translate into sales, cost pressure could persist.

Strategic direction and non-operating volatility

Liquor import-export and pet supply businesses were proposed for the articles of incorporation at a 2026 shareholder meeting, and the liquor type and overseas markets are undecided. Expansion into businesses unrelated to the core operations is cited as a risk for resource allocation and management focus.

Non-operating items such as impairment on investment property and fair-value losses on financial assets have repeatedly swung net results.

11

What to watch next

  1. December 31, 2026

    This is the fiscal year-end for 2026. It is the reference point for whether Q4 operating results return to profit or the widened operating loss seen in Q3 2026 continues.

  2. Early 2027 (annual preliminary results)

    This is the first disclosure to show whether 2026 annual sales exceed the KRW 55.9 billion of 2025 and whether the operating loss persists. The cumulative January to September 2026 figures of KRW 54.6 billion in revenue and KRW 1.1 billion in operating loss serve as the baseline for Q4.

  3. March 31, 2027

    This is the deadline for the 2026 annual report, the next periodic filing. It is where the operating margin, operating cash flow and any non-operating impairment losses will be confirmed.

  4. May 15, 2027

    This is the deadline for the Q1 2027 quarterly report. Because Q1 2026 posted an operating profit, whether that profit is maintained in Q1 2027 becomes the year-on-year comparison point.

  5. Timing not yet set

    Items to be confirmed through disclosures include progress on liquor import-export licensing, whether the rights offering is revived, and the completion timing of the Asan plant expansion. The funding method directly affects the capital structure and shareholder dilution.

12

Overall view

Kyung NAM Pharm's Q3 2026 revenue rose 46.2% to KRW 20.7 billion, extending a run of four consecutive quarters of sales growth, but the operating loss widened to KRW 1.31 billion, so an improvement in profitability has not yet been confirmed.

Operating losses ran every year from 2022 through 2025, and attributable net loss returned in 2025 at KRW 9.01 billion. Reports say the 2024 profit was driven largely by a one-off disposal gain, so the durability of earnings still needs testing.

On the balance sheet, the debt ratio fell to 43.7% at end-2025 from 85.5% in 2023, and total equity stood at KRW 108.3 billion. Operating cash flow, however, turned negative in 2025, and reports of a withdrawn rights offering have left the funding route uncertain.

Strengths include wider distribution, seven new products and a narrower quarterly loss in Q3 2026, while weaknesses include the Lemona-centered sales mix, cost pressure and repeated capital raising.

The next checkpoints are the 2026 preliminary annual results, the operating margin and operating cash flow in the 2026 annual report, and whether Q1 2027 returns to an operating profit.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. comp.wisereport.co.kr
  2. pharmnews.com
  3. v.daum.net
  4. pharmnews.com
  5. news.nate.com
  6. vegannews.co.kr
  7. medicaltimes.com
  8. newsthevoice.com
  9. m.news.nate.com
  10. biz.newdaily.co.kr
  11. kpinfo.kr
  12. m-i.kr
  13. m-i.kr
  14. bbn.kiwoom.com
  15. valueline.co.kr
  16. jobkorea.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis